dinitrophenyl(DNP)
PreclinicalSmall molecule
Novo Nordiskdinitrophenyl(DNP) is one of 46 small molecule programs targeting Melanoma. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
177 competitors in Melanoma
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Keytruda
Merck & Co.Phase 3
Cotellic
RochePhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Taxol
TevaPhase 3
Mektovi
PfizerPhase 3
Tecentriq
RochePhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Lenvima
EisaiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Melanoma1 trial
Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy
Completed·—··NCT02372708·72 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for dinitrophenyl(DNP). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company